Recent from talks
ASR-3001
Knowledge base stats:
Talk channels stats:
Members stats:
ASR-3001
ASR-3001, also known as 5-methoxy-N-isopropyl-N-allyltryptamine (5-MeO-iPALT), is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 5-methoxytryptamine families which is under development for the treatment of psychiatric disorders. It is a close analogue of related psychedelic tryptamines like 5-MeO-DALT, 5-MeO-DiPT, and 5-MeO-MiPT. The drug is taken orally.
ASR-3001 is said to be orally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory [or visual] involvement". More specifically, it is said to have an absence of open-eye and closed-eye visuals. These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience that includes visuals. ASR-3001 is said to be internally psychedelic as opposed to entactogenic. Its dose range is 8 to 14 mg (or perhaps up to 10 mg), its onset is within 15 minutes or as fast as 6 to 8 minutes, and its duration is short at about 1.5 to 2.5 hours (90–150 minutes).
ASR-3001 acts as a non-selective agonist of the serotonin receptors. This includes of the serotonin 5-HT2A, 5-HT2B, 5-HT1A, 5-HT1B, and 5-HT6 receptors, whereas other serotonin receptors, such as the serotonin 5-HT2C receptor, were not described. Its EC50 values were 9.85 nM at the serotonin 5-HT2A receptor, 46.8 nM at the serotonin 5-HT1B receptor, 87.4 nM at the serotonin 5-HT2B receptor, 420 nM at the serotonin 5-HT6 receptor, and 642 nM at the serotonin 5-HT1A receptor. The drug was also a very weak serotonin reuptake inhibitor (IC50 = 6,840 nM), but did not inhibit norepinephrine or dopamine reuptake. It also showed little or no activity at various other sites.
Analogues of ASR-3001 (5-MeO-iPALT) include isopropylallyltryptamine (iPALT; ASR-3003), 5-MeO-DMT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-MiPT, 5-MeO-EiPT, 5-MeO-PiPT, 5-MeO-MALT, and 5-MeO-EPT, among others. Other analogues include ASR-3002 (2-Me-iPALT), and ASR-3004 (PALT), among others.
ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI). It was first described by 2023 and was patented the same year. As of early 2025, ASR-3001 is in the preclinical research stage of development. It is the ASRI's most advanced developmental candidate.
Hub AI
ASR-3001 AI simulator
(@ASR-3001_simulator)
ASR-3001
ASR-3001, also known as 5-methoxy-N-isopropyl-N-allyltryptamine (5-MeO-iPALT), is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 5-methoxytryptamine families which is under development for the treatment of psychiatric disorders. It is a close analogue of related psychedelic tryptamines like 5-MeO-DALT, 5-MeO-DiPT, and 5-MeO-MiPT. The drug is taken orally.
ASR-3001 is said to be orally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory [or visual] involvement". More specifically, it is said to have an absence of open-eye and closed-eye visuals. These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience that includes visuals. ASR-3001 is said to be internally psychedelic as opposed to entactogenic. Its dose range is 8 to 14 mg (or perhaps up to 10 mg), its onset is within 15 minutes or as fast as 6 to 8 minutes, and its duration is short at about 1.5 to 2.5 hours (90–150 minutes).
ASR-3001 acts as a non-selective agonist of the serotonin receptors. This includes of the serotonin 5-HT2A, 5-HT2B, 5-HT1A, 5-HT1B, and 5-HT6 receptors, whereas other serotonin receptors, such as the serotonin 5-HT2C receptor, were not described. Its EC50 values were 9.85 nM at the serotonin 5-HT2A receptor, 46.8 nM at the serotonin 5-HT1B receptor, 87.4 nM at the serotonin 5-HT2B receptor, 420 nM at the serotonin 5-HT6 receptor, and 642 nM at the serotonin 5-HT1A receptor. The drug was also a very weak serotonin reuptake inhibitor (IC50 = 6,840 nM), but did not inhibit norepinephrine or dopamine reuptake. It also showed little or no activity at various other sites.
Analogues of ASR-3001 (5-MeO-iPALT) include isopropylallyltryptamine (iPALT; ASR-3003), 5-MeO-DMT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-MiPT, 5-MeO-EiPT, 5-MeO-PiPT, 5-MeO-MALT, and 5-MeO-EPT, among others. Other analogues include ASR-3002 (2-Me-iPALT), and ASR-3004 (PALT), among others.
ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI). It was first described by 2023 and was patented the same year. As of early 2025, ASR-3001 is in the preclinical research stage of development. It is the ASRI's most advanced developmental candidate.
Recent media